Get 20% lifetime commission for referring investors to digrin.com
here.
Immix Biopharma, Inc. (IMMX) Financials
IMMX Assets vs Liabilities
| Date | Assets | Liabilities |
|---|---|---|
| June 30, 2026 | 239.1 million | 10.2 million |
| March 31, 2026 | 95.8 million | 11.5 million |
| Dec. 31, 2025 | 104.8 million | 11.0 million |
| Sept. 30, 2025 | 20.1 million | 11.8 million |
IMMX Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
| Date | Free Cash Flow | Stock based compensation |
|---|---|---|
| June 30, 2026 | -11.8 million | 978140 |
| March 31, 2026 | -9.9 million | 575565 |
| Dec. 31, 2025 | -11.2 million | 570796 |
| Sept. 30, 2025 | -6.3 million | 470471 |
IMMX Net Income
No data available :(
IMMX Cash and Debt
Graph available only for paid members. Upgrade to see it.
| Date | Cash | Debt | Capital Lease |
|---|---|---|---|
| June 30, 2026 | 232.1 million | - | 1.0 million |
| March 31, 2026 | 90.6 million | - | 1.0 million |
| Dec. 31, 2025 | 100.4 million | - | 1.1 million |
| Sept. 30, 2025 | 15.9 million | - | 1.1 million |
IMMX Shares Outstanding
IMMX Expenses
Graph available only for paid members. Upgrade to see it.
| Date | Capex | R&D | G&A | S&M |
|---|---|---|---|---|
| June 30, 2026 | 21043 | 5.3 million | 7.1 million | - |
| March 31, 2026 | 32486 | 6.0 million | 4.8 million | - |
| Dec. 31, 2025 | 165126 | 5.7 million | 5.2 million | - |
| Sept. 30, 2025 | 372456 | 4.6 million | 3.1 million | - |
IMMX Cost of Revenue
Graph available only for paid members. Upgrade to see it.
| Date | Revenue | Cost of Revenue |
|---|---|---|
| June 30, 2026 | - | - |
| March 31, 2026 | - | 130766 |
| Dec. 31, 2025 | - | 90631 |
| Sept. 30, 2025 | - | - |
IMMX
Price: $11.34
52 week price:
Earnings Per Share: -0.88 USD
Exchange: NCM
Sector: Healthcare
Industry: Biotechnology
Country: United States
Volume: 12035
Market Capitalization: 781.0 million